Other
JAK Inhibitor
0
Pipeline Programs↗
4
Active Trials↗
0
Companies Involved↗
JAK Inhibitor is an early-stage landscape with 0 programs across 0 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
6
clinical trials
Not yet recruiting3 · 50%
Recruiting1 · 17%
Unknown status1 · 17%
Completed1 · 17%
Clinical Trials
Trial Activity
6 trials
Effect of JAK Inhibitor on Erosion Healing in RA
Recruiting·—·Phase 4·NCT05955066·60 enrolled
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT07454226·30 enrolled
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Not yet recruiting·—·Phase 2·NCT07447817·26 enrolled
JAK Inhibitor Treatment in AGS
Completed·—·Phase 2·NCT03921554·54 enrolled
PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors
Unknown status·LLiga Panamericana de Asociaciones de Reumatologia (PANLAR)·N/A·NCT04821206·3,000 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)